Schedule 13G ownership disclosure
Aclaris Therapeutics Inc
Common Stock · CUSIP: 00461U105
Event date: 2025-12-31
- Filing-level shares
- 6,700,629
- Percent of class
- 6.2%
- BlackRock, Inc.
Shares: 6,700,629 · Class: 6.2%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0002012383-26-000630
- Form type
- SCHEDULE 13G/A
- Filer
- Aclaris Therapeutics, Inc.
- CIK
- CIK 1557746
- Filed
- Jan 21, 2026
- Reporting period
- Dec 31, 2025
- Description
- Schedule 13G beneficial ownership